Certara Inc. (CERT)
NASDAQ: CERT
· Real-Time Price · USD
13.43
-0.43 (-3.10%)
At close: May 01, 2025, 3:15 PM
-3.10% (1D)
| Bid | 13.41 |
| Market Cap | 2.17B |
| Revenue (ttm) | 385.15M |
| Net Income (ttm) | -12.05M |
| EPS (ttm) | -0.08 |
| PE Ratio (ttm) | -167.87 |
| Forward PE | 26.16 |
| Analyst | Hold |
| Ask | 13.44 |
| Volume | 1,765,056 |
| Avg. Volume (20D) | 1,853,947 |
| Open | 13.87 |
| Previous Close | 13.86 |
| Day's Range | 13.02 - 13.94 |
| 52-Week Range | 8.63 - 17.94 |
| Beta | 1.64 |
About CERT
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulator...
Sector Healthcare
IPO Date Dec 11, 2020
Employees 1,487
Stock Exchange NASDAQ
Ticker Symbol CERT
Website https://www.certara.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CERT stock is "Hold." The 12-month stock price forecast is $16, which is an increase of 19.14% from the latest price.
Stock ForecastsNext Earnings Release
Certara Inc. is scheduled to release its earnings on May 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+11.54%
Certara shares are trading higher after the compan...
Unlock content with
Pro Subscription
2 weeks ago
+22.84%
Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.
